BU
SUPN icon

BBVA USA’s Supernus Pharmaceuticals SUPN Stock Holding History

BBVA USA’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$192K Sell
7,183
-378
-5% -$10.1K 0.01% 448
2021
Q2 		$233K Buy
+7,561
New +$232K 0.01% 441

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

BBVA USA's SUPN Position: Q3 2021 in Review

BBVA USA reduced its Supernus Pharmaceuticals (SUPN) stake by 5% in Q3 2021, selling an estimated $10.1K and leaving 7,183 shares worth $192K. The position accounts for 0.01% of the portfolio, ranked #448.

BBVA USA first reported a position in SUPN in Q2 2021 and has held it in 2 quarters since. The position peaked at $233K in Q2 2021. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • BBVA USA held 7,183 shares of Supernus Pharmaceuticals worth $192K as of Q3 2021.
  • BBVA USA sold 378 Supernus Pharmaceuticals shares in Q3 2021, an estimated $10.1K.
  • Supernus Pharmaceuticals made up 0.01% of BBVA USA's portfolio in Q3 2021, its #448 holding.
  • BBVA USA first reported a position in Supernus Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Supernus Pharmaceuticals position peaked at $233K in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.